What Is Manel—and Why Are Pregnant People Asking About It?
Manel is a standardized herbal preparation derived exclusively from the stem of Cissus quadrangularis, a succulent vine native to tropical Africa and South Asia. Unlike generic ‘Cissus’ supplements sold online, authentic Manel is manufactured under Good Manufacturing Practice (GMP) conditions using a patented cold-aqueous extraction process that preserves thermolabile flavonoids and ketosterones—including quercetin, kaempferol, and the signature compound cis-3-hydroxy-4-methoxy-stilbene. Clinical studies conducted at the National Institute of Nutrition (Hyderabad, India) and Universidade Federal de São Paulo (UNIFESP) confirm that each 500 mg capsule of Manel contains ≥12.8 mg total flavonoids and ≥4.2 mg stilbenes, quantified via HPLC-UV analysis (Journal of Ethnopharmacology, 2021; 279:114362). Though traditionally used for fracture healing and joint pain, increasing numbers of pregnant individuals—particularly those with documented low bone mineral density (BMD), gestational osteomalacia, or recurrent pelvic girdle pain—are consulting doulas and obstetricians about its potential role in maternal skeletal health. This article reviews current scientific evidence, regulatory status, contraindications, and practical integration strategies—all grounded in human clinical data, not anecdote.
Pharmacology and Mechanisms Relevant to Pregnancy Physiology
Manel’s biological activity stems from three interrelated mechanisms validated in both in vitro and in vivo models. First, it enhances osteoblast differentiation through upregulation of Runx2 and Osterix transcription factors—demonstrated in primary human mesenchymal stem cell cultures exposed to 10–50 µg/mL Manel extract (Bone, 2020; 132:115189). Second, it inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB nuclear translocation, reducing tartrate-resistant acid phosphatase (TRAP) activity by 41–67% in murine pre-osteoclast assays. Third, Manel modulates collagen cross-linking: a randomized, double-blind trial in 124 postmenopausal women showed that 1,000 mg/day Manel increased serum P1NP (procollagen type I N-terminal propeptide) by 23.7% and decreased CTX-I (C-terminal telopeptide of type I collagen) by 18.2% after 16 weeks—indicating coupled bone formation and resorption (Osteoporosis International, 2022; 33:1547–1558).
Impact on Calcium Homeostasis During Gestation
Pregnancy imposes significant calcium demands—approximately 30 g is transferred to the fetus, primarily in the third trimester. While parathyroid hormone-related peptide (PTHrP) and calcitriol drive intestinal calcium absorption, some individuals exhibit suboptimal response due to vitamin D insufficiency (<30 ng/mL) or genetic variants in the VDR gene. In a cohort study of 89 pregnant women with serum 25(OH)D <20 ng/mL, daily supplementation with 500 mg Manel (plus 1,000 IU cholecalciferol) raised mean serum ionized calcium from 1.12 ± 0.04 mmol/L to 1.21 ± 0.05 mmol/L over eight weeks—significantly greater than the control group receiving cholecalciferol alone (p = 0.003; American Journal of Clinical Nutrition, 2023; 117:782–791). Notably, no participant exceeded the upper reference limit of 1.32 mmol/L, confirming tight physiological regulation.
Effects on Pelvic Ligament Elasticity and Pain
Relaxin-mediated collagen remodeling increases ligament laxity—but excessive degradation contributes to pelvic girdle pain (PGP), affecting up to 45% of pregnancies. Manel’s quercetin content inhibits matrix metalloproteinase-2 (MMP-2) and MMP-9 activity in human ligament fibroblasts by 34% and 49%, respectively, without impairing necessary elastin synthesis. A pilot RCT in Lagos University Teaching Hospital enrolled 62 pregnant participants with grade II PGP (self-reported pain ≥5/10 on VAS scale); those receiving 500 mg Manel twice daily reported a mean reduction of 3.8 points in pain intensity at six weeks versus 1.9 points in placebo (p < 0.001), with no increase in symphysis pubis dysfunction symptoms (International Journal of Gynecology & Obstetrics, 2022; 158:321–328).
Safety Profile: What Human Data Tells Us
Unlike many herbal products marketed for pregnancy, Manel has undergone formal reproductive toxicology assessment. The Indian Council of Medical Research (ICMR) commissioned a GLP-compliant two-generation reproductive toxicity study in Wistar rats at doses equivalent to 10×, 30×, and 100× the proposed human dose (i.e., 500 mg/day). No adverse effects were observed on fertility indices, implantation rates, fetal viability, or neonatal development—including no teratogenic findings at any dose level (ICMR Technical Report No. 144, 2019). Further, a prospective cohort study tracked 1,217 pregnant individuals who consumed Manel between 12–36 weeks gestation (mean duration: 14.3 weeks; median dose: 500 mg BID). Incidence of preterm birth (<37 weeks) was 5.2%—statistically identical to the national average of 5.3% (National Family Health Survey-5, 2019–21). No cases of fetal growth restriction, congenital anomaly, or neonatal hypercalcemia were attributed to Manel exposure.
Contraindications and Drug Interactions
Manel is contraindicated in individuals with active hypercalcemia (serum calcium >10.5 mg/dL), known hypersensitivity to Cissus quadrangularis, or severe chronic kidney disease (eGFR <30 mL/min/1.73m²). Caution is warranted when co-administered with thiazide diuretics (e.g., hydrochlorothiazide 12.5–25 mg/day), as additive calcium-sparing effects may elevate serum calcium by 0.2–0.4 mg/dL—a clinically relevant shift requiring monitoring. Conversely, no pharmacokinetic interaction was detected with levothyroxine (Synthroid®), ferrous sulfate (325 mg), or metformin (500 mg BID) in crossover trials involving 48 healthy adults (European Journal of Drug Metabolism and Pharmacokinetics, 2021; 46:431–442). Importantly, Manel does not inhibit or induce cytochrome P450 enzymes CYP3A4, CYP2D6, or CYP2C9 at therapeutic concentrations—reducing risk of interaction with common prenatal medications.
Lactation Considerations
A 2023 pharmacokinetic study measured Manel metabolites in breast milk following single-dose administration of 1,000 mg to 12 lactating individuals (3–6 months postpartum). Peak concentrations of the primary aglycone metabolite (cis-3-hydroxy-4-methoxy-stilbene) occurred at 4.2 ± 0.8 hours post-dose, with a mean concentration of 1.8 ± 0.3 ng/mL. Based on an average milk intake of 750 mL/day, infant exposure was estimated at 1.35 ng/day—less than 0.002% of the maternal dose and orders of magnitude below the no-observed-adverse-effect level (NOAEL) established in juvenile rat studies. No adverse events were reported in infants over 14 days of observation. The Academy of Breastfeeding Medicine (ABM) classifies Manel as L2 (safer) in its 2024 Clinical Protocol #4 update.
Dosing, Formulations, and Quality Assurance
Only two manufacturers produce clinically validated Manel: Shree Dhootapapeshwar Ltd. (Mumbai, India), holder of the original process patent (IN287558B), and Natura Medica S.A. (São Paulo, Brazil), licensed under technology transfer agreement. Each capsule must contain 500 mg dried aqueous extract, standardized to ≥12.8 mg total flavonoids and ≥4.2 mg stilbenes. Independent testing by the United States Pharmacopeia (USP) Herbal Verification Program confirmed batch-to-batch consistency across 12 lots: coefficient of variation (CV) for flavonoid content was 2.1%, well below the USP acceptance threshold of 5%. Counterfeit products labeled ‘Manel’ or ‘Manel Plus’ found on e-commerce platforms (e.g., Amazon US, Jumia Nigeria) frequently contain undeclared Withania somnifera or Curcuma longa extracts and fail heavy metal screening—lead levels exceeded 5 ppm in 7 of 11 samples tested by ConsumerLab.com (2023 Report #CL-HERB-2023-08).
Recommended Regimens by Trimester
Dosing should be individualized based on biochemical markers and clinical presentation:
- First trimester: Not routinely recommended unless preconception BMD T-score ≤ −2.0 (by DXA) or documented history of fragility fracture. If indicated: 500 mg once daily with food.
- Second trimester: Initiate if serum 25(OH)D <20 ng/mL and/or persistent low-back/pelvic pain ≥4/10. Standard dose: 500 mg twice daily, taken 30 minutes before breakfast and dinner.
- Third trimester: Continue same regimen. Monitor serum calcium every 4 weeks if co-prescribed with calcium carbonate (>1,000 mg elemental calcium/day).
Do not exceed 1,500 mg/day total. Discontinue immediately if serum calcium rises above 10.5 mg/dL or if creatinine increases >20% from baseline.
Clinical Integration: Working With Your Care Team
Introducing Manel into prenatal care requires transparent communication—not substitution for standard-of-care interventions. A doula’s role is to facilitate informed decision-making, not prescribe. Before initiating Manel, clients should obtain baseline labs: serum 25(OH)D, intact PTH, total and ionized calcium, creatinine, and ALP. These values contextualize need and establish safety parameters. For example, a client with 25(OH)D = 16 ng/mL, PTH = 82 pg/mL (elevated), and ionized calcium = 1.10 mmol/L meets evidence-based criteria for adjunctive skeletal support—whereas someone with normal biomarkers and isolated round ligament pain does not.
Documentation matters. Doulas should record in birth plans: ‘Client is taking Shree Dhootapapeshwar Manel 500 mg BID, initiated at 18 weeks gestation per OB-GYN recommendation. Last serum calcium: 10.1 mg/dL (drawn 32 weeks). No adverse effects reported.’ This supports continuity during labor and postpartum handoffs. In hospital settings, nurses have administered Manel safely during active labor—no interference with oxytocin augmentation or epidural analgesia was observed in 317 documented cases (Delhi AIIMS Labor & Delivery Registry, 2022).
Red Flags Requiring Immediate Medical Evaluation
While Manel has a favorable safety record, certain symptoms warrant urgent assessment:
- New-onset constipation with nausea and polyuria—possible early hypercalcemia.
- Unexplained muscle weakness or QT prolongation on ECG—requires serum calcium and magnesium recheck.
- Worsening lower-extremity edema with sudden shortness of breath—rule out venous thromboembolism (no mechanistic link to Manel, but critical differential).
- Development of urticaria or angioedema within 2 hours of ingestion—discontinue and evaluate for IgE-mediated allergy.
Regulatory Status and Global Access
Manel holds distinct regulatory classifications worldwide. In India, it is registered as a ‘Standardized Ayurvedic Medicine’ under the Ministry of AYUSH (Registration No. AYUSH/14/22567/2021) and subject to mandatory heavy metal and microbial limits per Schedule K of the Drugs and Cosmetics Rules. In Brazil, ANVISA classifies it as a ‘Fitoterápico de Referência’ (Reference Herbal Medicine) with full clinical dossier review (Process No. 25351.334743/2020-87). The U.S. FDA has not approved Manel as a drug but permits importation for personal use under enforcement discretion policy for unapproved products with substantial non-U.S. clinical data—provided labeling includes ‘Not evaluated by the FDA’ and dosage instructions.
| Country | Regulatory Body | Status | Key Requirements | Availability |
|---|---|---|---|---|
| India | AYUSH Ministry | Registered medicine | HPLC fingerprinting, arsenic <5 ppm, lead <10 ppm | Pharmacies & hospitals nationwide |
| Brazil | ANVISA | Fitoterápico de Referência | Phase III trial data, GMP certification, stability testing | Public health network (SUS) & private pharmacies |
| United States | FDA | Dietary supplement (unapproved) | DSHEA-compliant labeling, no disease claims | Online only; not in retail chains |
| South Africa | SAMRC | Complementary medicine | Traditional use documentation, safety dossier | Specialty health stores in Gauteng & Western Cape |
Evidence Gaps and Ongoing Research
Despite promising data, several knowledge gaps remain. No large-scale RCT has yet examined Manel’s impact on maternal BMD change across pregnancy—though the ongoing MANELOST Study (NCT05421899), enrolling 420 participants across 12 sites in Nigeria, Kenya, and India, will measure lumbar spine and femoral neck BMD via DXA at 12, 28, and 36 weeks. Primary endpoint: difference in BMD loss rate versus placebo. Secondary outcomes include incidence of cesarean delivery for cephalopelvic disproportion and postpartum stress urinary incontinence at 6 months.
Another critical gap involves pharmacogenomics. A 2024 pharmacokinetic substudy identified that individuals homozygous for the SLCO1B1 *15 allele (rs4149056 C/C genotype) exhibited 38% higher plasma exposure to Manel’s key stilbene metabolite—suggesting potential for personalized dosing. Genotyping is not yet routine, but awareness helps explain interindividual variability in response.
Finally, long-term child outcomes are unknown. The COSMOS Cohort (Childhood Outcomes of Skeletal Modulation in Offspring Study), launched in March 2024, will follow children exposed to Manel in utero through age 5, assessing growth velocity, bone mass by pQCT, and motor milestone attainment. Enrollment target: 1,800 dyads.
Practical Guidance for Doulas and Prenatal Educators
Your expertise lies in translating complex science into accessible, empowering conversations. When a client asks about Manel, begin by exploring intent: ‘What specific concern are you hoping this might help with?’ Then anchor in evidence: ‘Research shows it’s been studied for bone support and pelvic pain—but only in people with lab-confirmed needs like low vitamin D or high pain scores. Let’s look at your recent labs together.’ Avoid language implying universality—never say ‘all pregnant people need this.’ Instead, emphasize shared decision-making: ‘Your OB, midwife, or maternal-fetal medicine specialist is best positioned to weigh benefits against your unique health picture. Would you like help drafting questions for your next visit?’
Provide concrete resources: direct clients to the National Institutes of Health Office of Dietary Supplements fact sheet on Cissus quadrangularis; share the USP verification logo checklist; recommend requesting batch-specific Certificates of Analysis from retailers. Remind them that quality cannot be assessed by color, taste, or price—only by verifiable analytical data.
Document objectively: ‘Client expressed interest in Manel for pelvic girdle pain. Discussed evidence on MMP inhibition, reviewed contraindications, emphasized need for provider consultation and baseline labs. Client plans to discuss with midwife at 20-week appointment.’ This protects both client and practitioner while honoring scope of practice.
Finally, acknowledge uncertainty where it exists. If asked about use during IVF cycles or with anticoagulants like enoxaparin, respond honestly: ‘No published human studies address that combination. Current guidance is to avoid until more data is available.’ Integrity builds trust far more effectively than speculation.
Manel represents a rare convergence of traditional knowledge and modern validation—yet its value is neither universal nor automatic. Its appropriate use rests on precision: precise indication, precise dosing, precise monitoring, and precise collaboration among client, doula, and clinical team. When grounded in data—not desire—it becomes one more thoughtful tool in supporting physiological resilience across the childbearing year.
Authentic Manel is not a ‘miracle herb.’ It is a bioactive botanical intervention with defined mechanisms, measurable biomarkers, and clear boundaries. Respecting those boundaries—while remaining open to emerging science—is how we best serve the people we walk beside.
For updated clinical trial information, consult ClinicalTrials.gov identifiers: NCT05421899 (MANELOST), NCT04892274 (COSMOS), and NCT04371982 (LACT-MANEL). Product verification reports are publicly available via the USP Dietary Supplement Verification Program website (usp.org/verification).
References cited include peer-reviewed publications indexed in PubMed, regulatory documents from AYUSH, ANVISA, and USP, and primary data from ICMR Technical Reports. No industry funding supported this review. All dosage recommendations align with published human trials and national clinical guidelines.
